MHE Staff

Iyuzeh is a preservative-free latanoprost product that can be stored at room temperature. It has a list price of $299 for a month’s supply.

By offering pre-conception, pregnancy, postpartum, and newborn interventions, as well as primary, wellness, and preventive care, this mobile health center is set to close the access gaps that have long affected the well-being of women and children in Texas.

Early results are expected late next year from the phase 1 trial, which is being funded by the National Institute of Allergy and Infecious Diseases, the Bill & Melinda Gates Foundation and Vir Biotechnology, a San Franciso biotech company focused on vaccines and infectious disease.

The FDA has granted priority review and assigned a Prescription Drug User Fee Act date of March 14, 2024, for resmetirom to treat adult patients with nonalcoholic steatohepatitis (NASH) who have liver fibrosis.

This average rate decrease will lower total premiums by an estimated $130 million.

The keynote speaker for the three-day meeting in Orlando is Sampson Davis, M.D., an emergency medicine physician in New Jersey, an inspirational speaker and co-author of three best-selling books.

The submissions to both the FDA and the EMA are supported by two phase 3 trials demonstrating Skyrizi achieved the primary endpoint of clinical remission.

Sandoz’s Tyruko, the first biosimilar to Biogen’s Tysabri, is expected to be available as soon as possible. Pricing has not yet been made available.

Izervay, which is administered with an intravitreal injection, is expected to be available within the two to four weeks.

Xdemvy is the first treatment that directly targets the mites involved in Demodex blepharitis. It is expected to be available by the end of August 2023 and will have a list price of $1,850 per prescription.

Ycanth is the first drug to treat children and adults with molluscum contagiosum, a viral skin infection. It will be available in September, but pricing information has not yet been released.

Results of Sanofi-sponsored study presented at ISPOR meeting also show lower hospitalization rates among app users.

More than two-thirds (68%) of the respondents to the survey expressed confidence that the COVID-19 is "behind us." An overwhelming majority (80%), though, indicated that annual COVID-19 vaccination will be needed for the foreseeable future.

Roctavian (valoctocogene roxaparvovec), the gene therpay for hemophilia A, gets nods as holding the most promise among the drugs in the pipeline.

Survey results published in today's Morbidity and Mortality Weekly Report show ventilation strategies were not reported by more than 51% of school districts. Of those that reported, low-tech and inexpensive continuous airflow, which can involve opening windows and using fans, was most popular.

Expenditures break down from managed care, out of pocket, investments and others. In 2022, the dominant share was held by managed care segment.

Amongst a few recommendations, Commonweath is encouraging how and how much we as payers, providers and consumers pay for primary care.

The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for prescription digital therapeutics.

The Drug Enforcement Administration (DEA) announced proposed permanent rules for the prescribing of controlled medications through telemedicine with new appropriate safeguards.

The American Cancer Society has introduced the American Cancer Society Center for Diversity in Cancer Research Training to address the lack of diversity in research environments. The new center will enhance the traditional academic journey, focusing on meeting potential researchers where they are and helping them overcome barriers to future success.

Digital therapeutics are regulated like devices by the FDA. Andy Molnar, the CEO of the industry’s trade organization, the Digital Therapeutics Alliance, says the FDA clearance and authorization process for digital therapeutics “works.”

Data collected from more than 40,000 practitioners revealed the top healthcare trends that will have the biggest impact on physicians and medical offices in 2023. Among them were patient-centric care, remote patient monitoring and mental healthcare.

Developer of EndeavorRx, a game-based treatment for ADHD, is pulling back from the pipeline and focusing on near-term growth, the CEO said in an email to employees.

Pear also recently announced a deal with California's Medicaid program that involves supporting a pilot project to help people with stimulant use disorder.

Biosimilars started to gain a firm foothold in the market this year and could take off in 2023 with the advent of Humira biosimilars. Our articles about biosimilars were some of the most viewed of the year.

Pharmacy benefit managers (PBMs) were in the news in 2022, and Managed Healthcare Executive®’s coverage of PBMs garnered a great deal of attention.

A one-stop-shop for 2022 cover stories.

Amendola Communications collected 10 predictions for developments in healthcare in 2023 from leaders in the field.